10-Q · May 12, 2026
Connect Biopharma reported minimal license revenue of $0.2 million for Q4 2026, a decline from $0.0 million in the prior year, with an EPS loss slightly improving from -0.27 to -0.30. The company increased its cash…
Earnings analysis · 10-Q
CNTB earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Connect Biopharma delivered a substantial revenue increase to $2.768 million, versus $48,000 in the prior-year quarter and $169,000 in the prior quarter, while diluted EPS improved sequentially to $(0.27) but remained…
Read full summary
Connect Biopharma delivered a substantial revenue increase to $2.768 million, versus $48,000 in the prior-year quarter and $169,000 in the prior quarter, while diluted EPS improved sequentially to $(0.27) but remained worse year over year than $(0.23). The key operating catalyst is completion of enrollment in the 160-participant asthma and 159-participant COPD Phase 2 studies, with topline data expected in September 2026. However, the $17.284 million net loss and $16.273 million of R&D expense highlight continued high cash burn; management expects the $31.5 million cash balance to fund operations for at least one year. The 10-Q states that there were no material changes to the risk factors in the 2025 Annual Report and provides no numeric financial guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.27
What stood out
-
Revenue Increased Sharply
Second-quarter revenue was $2.768 million, up from $48,000 in the prior-year quarter and $169,000 in the prior quarter, reflecting a significant milestone-related increase.
-
Sequential EPS Improvement
Diluted EPS was $(0.27), improving from $(0.34) in the prior quarter but worsening from $(0.23) in the prior-year quarter.
-
Seabreeze STAT Enrollment Complete
Enrollment was completed in the 160-participant asthma and 159-participant COPD Phase 2 Seabreeze STAT studies, with topline data expected in September 2026.
-
At Least One Year of Cash Runway
Management stated that the $31.5 million cash balance is expected to fund operations for at least one year from the release date.
-
Controls Deemed Effective
As of June 30, 2026, management concluded that disclosure controls and procedures were effective at the reasonable-assurance level.
What to watch
-
Wider Net Loss
Net loss increased to $17.284 million, indicating substantial ongoing cash consumption despite the $2.768 million revenue milestone in the quarter.
-
Elevated Clinical Spending
Research and development expense rose to $16.273 million as the company completed enrollment in two Phase 2 studies, increasing near-term spending ahead of the September 2026 data readout.
-
Potential Insider-Share Supply
The company has no material legal proceedings, but two executives adopted trading arrangements covering sales of up to 400,000 and 77,591 ordinary shares, respectively, during the quarter.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects topline results from the 160-participant asthma and 159-participant COPD Phase 2 Seabreeze STAT studies in September 2026 and expects the $31.5 million cash balance to fund operations for at least one year from the release date.
Earlier filings 3
10-K · March 31, 2026
Connect Biopharma is a clinical-stage company focused on rademikibart, an IL-4Rα monoclonal antibody targeting acute exacerbations of asthma and COPD; it initiated two parallel Phase 2 trials in May 2025 and expects…
10-Q · November 12, 2025
Connect Biopharma reported Q3 license revenue of $16,000 and a GAAP net loss of $17.2 million (EPS $(0.31)), driven by higher R&D spend. Cash and short-term investments totaled $54.8 million as of September 30, 2025 and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.